Compare BTBD & PMCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BTBD | PMCB |
|---|---|---|
| Founded | 1987 | 1996 |
| Country | United States | United States |
| Employees | 188 | N/A |
| Industry | Restaurants | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.0M | 8.3M |
| IPO Year | N/A | 2001 |
| Metric | BTBD | PMCB |
|---|---|---|
| Price | $2.09 | $0.76 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 801.5K | 111.9K |
| Earning Date | 05-14-2026 | 03-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 277.22 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.00 | $0.63 |
| 52 Week High | $5.59 | $1.51 |
| Indicator | BTBD | PMCB |
|---|---|---|
| Relative Strength Index (RSI) | 57.85 | 55.07 |
| Support Level | $1.58 | $0.65 |
| Resistance Level | $2.14 | $0.78 |
| Average True Range (ATR) | 0.23 | 0.06 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 56.67 | 77.64 |
BT Brands Inc operates and owns a fast-food restaurant called Burger Time. Its offerings include a variety of burgers and other affordable items, including sides and soft drinks. The company owns and operates Keegan's Seafood Grille (Keegan's), a dine-in restaurant located in Florida; Pie In The Sky Coffee and Bakery (PIE), located in Massachusetts; and Schnitzel Haus, a German-themed restaurant located in Florida. The company's revenues are derived from the sale of food and beverages at its restaurants.
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.